There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin (NASDAQ: BMRN) and Spark Therapeutics (NASDAQ: ONCE) with bullish sentiments.
BioMarin (NASDAQ: BMRN)
Canaccord Genuity analyst Michelle Gilson assigned a Buy rating to BioMarin (NASDAQ: BMRN) yesterday and set a price target of $101. The company’s shares closed yesterday at $87.61.
Gilson commented:
“We view these long-term data positively as FVIII levels are high enough to prevent bleeds. At week 104 for the 6E13 vg/kg dose, no patients exceeded the upper limit of normal FVIII activity, which is encouraging, though levels still may not be stabilized at this point. Mean ABR decreased from 16.3 to 0.5 and mean FVIII use decreased from 137 to 5.3 infusions/year. All patients are off prophylaxis. At week 52 for the 4E13 vg/kg dose, FVIII activity didn’t change much from last update, though reductions in mean ABR/FVIII usage were impressive.”
Gilson has an average return of 0.7% when recommending BioMarin.
According to TipRanks.com, Gilson is ranked #541 out of 4801 analysts.
Currently, the analyst consensus on BioMarin is Strong Buy and the average price target is $117.36, representing a 34.0% upside.
In a report issued on May 7, Leerink Partners also reiterated a Buy rating on the stock with a $145 price target.
See today’s analyst top recommended stocks >>
Spark Therapeutics (NASDAQ: ONCE)
In a report released yesterday, Phil Nadeau from Cowen & Co. assigned a Buy rating to Spark Therapeutics (NASDAQ: ONCE), with a price target of $85. The company’s shares closed yesterday at $74.83.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 13.4% and a 55.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Spark Therapeutics is Moderate Buy and the average price target is $83.70, representing an 11.9% upside.
In a report issued on May 8, William Blair also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
